A Novartis-funded analysis gives the Novaritis MS drug the nod based on a model using efficacy and safety data.
Kesimpta (ofatumumab) is more cost effective than nearly all other approved first-line treatments for relapsing-remitting multiple sclerosis (RRMS), according to the results of a recent study conducted in Canada.
Moogeh Baharnoori, M.D., M.Sc., and Canadian colleagues evaluated the cost effectiveness of Kesimpta and other therapies along with best supportive care.
Their results, published in PharmacoEconomics-Open in September, showed that among first-line indicated therapies for RRMS, Kesimpta was dominant (more effective and had lower costs) over Aubagio (teriflunomide), interferons, Tecfidera (dimethyl fumarate), and Ocrevus (ocrelizumab).
“From a Canadian public healthcare system perspective, ofatumumab (Kesimpta) is cost effective against all currently approved and reimbursed disease-modifying therapies (DMTs) for the treatment of relapsing-remitting multiple sclerosis (RRMS), and dominant compared with all disease-modifying therapies with a first-line indication, except glatiramer acetate,” said the "keypoints" call-out in the article.
In contrast to other monoclonal antibodies, which are given intravenously, Kesimpta — the article used the generic name — is delivered with a subcutaneous injection that can be self-administered at home, allowing greater patient independence, reduced healthcare resource utilization, and access to treatment in areas that aren’t near infusion facilities, she said.
Kesimpta is approved in Canada for initial RRMS therapy but is often reserved for patients with more aggressive disease, Baharnoori noted in the PharmacoEconomics Open article.
Baharnoori is medical director of the Kingston Multiple Sclerosis Clinic and an assistant professor of neurology at the Department of Medicine at Queen’s University in Kingston, Ontario. The study was supported Novartis Pharmaceutical Canada. Novartis makes and markets Kesimpta.
Compared with glatiramer acetate (Copaxone, other brand names) and best supportive care, ofatumumab had incremental cost-effectiveness ratios (ICERs) of $24,189 Canadian dollars per quality-adjusted life-year (QALY) and $28,014/QALY, respectively, according to the Baharnoori and her colleagues.
At a willingness-to-pay threshold of $50,000/QALY, ofatumumab had a 64.3% probability of being cost effective. Among second-line therapies (scenario analysis), ofatumumab dominated natalizumab and fingolimod and resulted in an ICER of $50,969 versus cladribine.
Kesimpta is approved in Canada for initial RRMS therapy but is often reserved for patients with more aggressive disease, Baharnoorinoted in the PharmacoEconomics Open article.
In Canada, five disease-modifying therapies (DMTs) have high efficacy (average relapse reduction > 50%): Gilenya (fingolimod) and cladribine (Mavenclad, others), which are oral medication, and the injectable monoclonal antibodies, including Tysabri (natalizumab), Ocrevus, and Lemtrada (alemtuzumab), according to Baharnoori.
“Evidence suggests that patients have better disease outcomes (i.e., slower disease progression and reduced long-term disability) when higher efficacy treatments are initiated earlier in the disease course,” Baharnoori said. “However, most higher efficacy DMTs associated with increased risk of adverse events , limiting treatment to patients with persistent or high initial disease activity due to a suboptimal response to other DMTs.”
This data is based off of a study conducted by a group of researchers led by Niklas Frahm from the German Multiple Sclerosis Registry to compare the characteristics of patients with MS who switched from their first disease-modifying therapies (DMT) with those of patients who continued taking their first DMT.
Read More
Most Real-World Studies Report Positive Outcomes of Rituximab Use in Multiple Sclerosis
May 8th 2024Although several clinical trials have confirmed the safety and efficacy of rituximab in oncology and autoimmune disease, and even as off-label use in MS, real-world evidence is still necessary to help guide clinicians and managed care professionals in their treatment and coverage decision-making.
Read More
Diabetes Weight Loss Drugs Could be Linked to Reduced Risk of MS, Study Finds
April 12th 2024Drug repurposing has recently emerged as an attractive pathway for developing new treatments due to its relatively fast and cost-efficient trajectory. Because obesity and MS share inflammatory properties, researchers used data from the FDA Adverse Event Reporting System to investigate the association between weight loss-inducing drugs and MS
Read More
Specialty Pharmacist Interventions Result in More Than $150,000 in Cost Avoidance For MS Patients
April 4th 2024Darina Georgieva, Pharm.D., and her colleagues from the department of pharmaceutical services at Vanderbilt University Medical Center, conducted a retrospective observational study to learn the costs avoided through specialty pharmacist interventions for patients at the Vanderbilt MS Clinic. The study results were published in the Journal of Managed Care and Specialty Pharmacy earlier this month.
Read More